340B Health supported HRSA’s assistance as an acceptable implementation of the 340B legislation’s orphan medication exclusion. Many of these medications can cost sufferers up to $300,000 per year or more, and without usage of 340B discounts, these hospitals will struggle to meet the needs of their vulnerable patients. This is a significant setback for rural hospitals who already are struggling to keep their doors open up, said Ted Slafsky, 340B Health’s Chief and President Executive Officer. 340B Health is an association of over 1000 hospitals that take part in the 340B program.. PRESS RELEASE 340B Health is normally deeply disappointed with a federal government district court ruling today that will significantly raise the price of orphan drugs for rural and malignancy hospitals and their sufferers.First Quarter 2014 Crucial Highlights and Accomplishments Achieved record first quarter consolidated revenue of $90.6 million, a rise of 23 percent over last year's first quarter. Generated record operating cash flow of $23.4 million. Completed the acquisition of Hi-Tech Pharmacal Co., Inc. on April 17. The acquisition adds scale, breadth of dosage and products forms, and additional diversification of the Business's item portfolio. Raj Rai, Chief Executive Officer commented, ‘We are thrilled with the fantastic start that we've seen for 2014. Our team continues to execute on multiple growth initiatives. Furthermore to completing the transformative acquisition of Hi-Tech a few weeks ago, we acquired two more branded ophthalmic products also, getting to five the branded ophthalmic products acquired over the last couple of months.